Compare ACADIA Pharmaceuticals Inc. (ACAD) vs United Microelectronics Corp (UMC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs United Microelectronics Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.79 (market cap $4.49B), while United Microelectronics Corp trades at $24.79 (market cap $60.80B). The key difference: United Microelectronics Corp is far larger — about 13.5× ACADIA Pharmaceuticals Inc.'s market cap, and United Microelectronics Corp pays a 1.73% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | UMC | |
|---|---|---|
Market Cap | $4.49B | $60.80B |
Sector | Health | Technology |
52-Week High | $28.06 | $28.02 |
52-Week Low | $20.06 | $6.58 |
Enterprise Value | $3.69B | $58.38B |
Dividend Yield | — | 1.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
UMC trades at $23.83, down 2.89% on the day, with a bullish technical signal from moving averages and recent earnings beats. Revenue grew to $237.55 billion in 2025, though net income margin compressed to 16.99%. The company maintains strong cash flow from operations and announced a $0.41 dividend for H2-26, reflecting financial stability amid competitive semiconductor market dynamics.
Outlook remains supported by specialty chip demand and 14nm eHV platform innovation, but valuation multiples like P/E of 41.94 suggest premium pricing. Risks include margin pressure and industry cyclicality, while analyst consensus leans hold with 53.33% neutral ratings, indicating cautious optimism for long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
